Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2positive non-breast advanced solid tumors.

被引：0
|
作者：
Wang, Jianzheng
Zhang, Baiwen
Cheng, Xiaojiao
Li, Qingli
Lv, Huifang
Nie, Caiyun
Chen, Beibei
Xu, Weifeng
Zhao, Jing
He, Yunduan
Tu, Shuiping
Chen, Xiaobing
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Gastrointestinal Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Zheng zhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15064
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2positive breast cancer: a network meta-analysis
    Gan, Lu
    Li, Fangxuan
    Su, Jialin
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Neoadjuvant and adjuvant treatment of patients with HER2positive early breast cancer
    Harbeck, N.
    BREAST, 2021, 56 : S3 - S4
  • [23] Efficacy, toxicity and prognostic factors of pyrotinib-involved neoadjuvant therapy in HER2-positive breast cancer: A retrospective study
    Wang, Hao
    Cao, Hailing
    Guo, Zhiyun
    ONCOLOGY LETTERS, 2023, 26 (01)
  • [24] Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
    Zhang, Lili
    Wu, Xiaohong
    Zhou, Jun
    Zhu, Mingzhen
    Yu, Hao
    Zhang, Yusong
    Zhao, Yutian
    Han, Zhengxiang
    Guo, Yujiang
    Guan, Xiaoqing
    Wang, Xufen
    Xu, Hong
    Sun, Li
    Zhang, Jiaxin
    Zhuang, Min
    Xie, Li
    Yu, Shiyou
    Chen, Ping
    Feng, Jifeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] Efficacy and Safety of Hetrombopag for Thrombocytopenia in Patients with Advanced Solid Tumors: A Retrospective Study
    Liu, Haonan
    Ma, Xiao
    Pan, Di
    Cao, Menghan
    Han, Zhengxiang
    Wang, Hongmei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023, 2023
  • [26] Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2+ breast cancer with brain metastasis: a retrospective cohort study
    Chen, Jiaxin
    Zhang, Huiqiang
    Zhou, Jinmei
    Wu, Zisheng
    Wu, Xuexue
    Zhang, Shaohua
    Jiang, Zefei
    Wang, Tao
    ANNALS OF TRANSLATIONAL MEDICINE, 2022,
  • [27] Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study
    Zhang, Xiaoling
    Li, Zhaohui
    Han, Linlin
    Lv, Zheng
    Teng, Yuee
    Cui, Xiujie
    Zhou, Caiyun
    Wu, Hongwei
    Fang, Wei
    Xu, Lingzhi
    Zhao, Shanshan
    Song, Chen
    Zheng, Yuanyuan
    Gao, Tianqi
    Li, Man
    ONCOTARGETS AND THERAPY, 2022, 15 : 1067 - 1078
  • [28] Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
    Li, Bob T.
    Li, Tianhong
    Johnson, Melissa Lynne
    Waqar, Saiama Naheed
    Zhu, Viola Weijia
    Ou, Sai-Hong Ignatius
    Lin, Jessica Jiyeong
    Wang, Ding
    Shapiro, Geoffrey
    Wang, Judy Sing-Zan
    Liu, Dazhi
    Ye, Yuqing
    Kosar, Hana
    Hee, Angela
    Berk, Greg
    Zhang, Sean
    Wang, Junsheng
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Chunyu Tian
    Minghui Wang
    Hancheng Liu
    Jianping Liu
    Mengze Xu
    Lihui Ma
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1041 - 1049
  • [30] A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer
    Qian, J.
    Yang, H.
    Zhu, C.
    Tan, J.
    Liu, Z.
    Chen, M.
    Zhou, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S934 - S934
12345